Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain
- Authors: Mercadante, S; Porzio, G; Adile, C; Aielli, F; Cortegiani, A; Dickenson, A; Casuccio, A.
- Publication year: 2014
- Type: Articolo in rivista (Articolo in rivista)
- Key words: Adverse effects; Cancer pain; Palliative care; Tapentadol;
- OA Link: http://hdl.handle.net/10447/96904
Abstract
Objective: The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in patients who were already treated by opioids. Methods: A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer patients who were receiving at least 60 mg of oral morphine equivalents were selected. Patients discontinued their previous opioid analgesics before starting TP, in doses calculated according the previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were changed according to the patients' needs for a period of 4 weeks. Oral morphine was offered as a breakthrough pain medication. Pain and symptom intensity were recorded at weekly intervals. Distress score (DS) was calculated from the sum of symptom intensities. TP opioid escalation indexes (TPEI) for the study period were calculated. Results: Nineteen patients were male, and the mean age was 63.5 years (±11.5). The mean K...